GC Genome Corporation announced the publication of a new study in Radiation Oncology Journal, which demonstrates the feasibility of cell-free DNA monitoring to predict treatment response and detect minimal residual disease after radiation therapy in solid tumor patients using I-score, a tool for calculating genomic instabilities developed by GC Genome.
